Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.

ABSTRACT: Although only a small fraction will ever develop the active form of tuberculosis (ATB) disease, chemoprophylaxis treatment in latent TB infected (LTBI) individuals is an effective strategy to control pathogen transmission. Characterizing immune responses in LTBI upon chemoprophylactic treatment is important to facilitate treatment monitoring, and thus improve TB control strategies. Here, we studied changes in the blood transcriptome in a cohort of 42 LTBI and 8 ATB participants who received anti-TB therapy. Based on the expression of previously published gene signatures of progression to ATB, we stratified the LTBI cohort in two groups and examined if individuals deemed to be at elevated risk of developing ATB before treatment (LTBI-Risk) differed from others (LTBI-Other). We found that LT

SUBMITTER: Burel JG 

PROVIDER: S-EPMC8629963 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature